London · Delayed Price · Currency is GBP · Price in GBX GENinCode Company Description
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient’s health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally.
The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart diseases, such as cardiomyopathies, channelopathies, and aortopathies related with sudden cardiac death syndrome.
It also provides THROMBO inCode, a genetic test for the diagnosis of hereditary thrombophilia and for assessing the patient's risk of thrombosis; THROMBO inCode reproductive health, a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and risk of ovarian cancer algorithm test product.
In addition, the company is involved in Medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
| Country | United Kingdom |
| Founded | 2018 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Matthew Walls |
Contact Details
Address: One St. Peters Square Manchester, M2 3DE United Kingdom | |
| Phone | 44 1865 676 125 |
| Website | genincode.com |
Stock Details
| Ticker Symbol | GENI |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BL97B504 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Matthew Walls | Chief Executive Officer |
| Paul Andrew Foulger | Chief Financial Officer |
| Jordi Puig Gilberte | Chief Operating Officer |